Abstract
Background: Breakthrough infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529) has occurred in populations with high vaccination rates.
Methods: In a longitudinal cohort study, pre-breakthrough infection sera for Omicron breakthroughs (n = 12) were analyzed. Assays utilized include a laboratory-developed solid phase binding assay to recombinant spike protein, a commercial assay to the S1 domain of the spike protein calibrated to the World Health Organization (WHO) standard, and a commercial solid-phase surrogate neutralizing activity (SNA) assay. All assays employed spike protein preparations based on sequences from the Wuhan-Hu-1 strain.
Results: Pre-breakthrough binding antibody titers ranged from 1:800 to 1:51,200 for the laboratory-developed binding assay, which correlated well and agreed quantitatively with the commercial spike S1 domain WHO calibrated assay. SNA was detected in 10/12 (83%) samples.
Conclusions: Neither high binding titers nor SNA were markers of protection from Omicron infection/re-infection.
Keywords: Binding antibodies; Breakthrough; Neutralizing antibodies; Omicron; SARS-CoV-2.
【저자키워드】 Neutralizing antibodies, omicron, SARS-CoV-2., breakthrough, binding antibodies, 【초록키워드】 SARS-CoV-2, coronavirus, variant, Infection, Population, Spike protein, Neutralizing activity, sera, WHO, B.1.1.529, binding, Recombinant spike protein, marker, binding antibody, World Health Organization, acute respiratory syndrome, longitudinal cohort study, sequence, vaccination rates, Wuhan-Hu-1, S1 domain, analyzed, occurred, include, the spike protein, correlated, ranged, calibrated, 【제목키워드】 neutralizing antibody, SARS-CoV-2, Breakthrough infection, binding, individual, Permissive,